Service des maladies du sang, Hôpital Saint-Louis, Université Paris-VII, 75462 Paris, France
Immune thrombocytopenic purpura (ITP) is often chronic in adults. Several recent contributions have shed new light on ITP epidemiology and physiopathology. Since the publication of treatment recommendations from several expert panels, novel therapeutic options have emerged, including rituximab and thrombopoietin agonists (TPO). Here we review the recent advances on chronic ITP physiopathology, epidemiology and management in adults.